Filters
Sequences for determination of the transcription activity and expression levels of the target gene for 5-azacitidine treatment
Oligonucleotide sequences, designed to measure the relationship between abundance and localization of key molecular factors in samples of tumor cells towards improvement of the diagnosis, prognosis and estimate the potential effectiveness of treatmen...
EB - Genetika a molekulární biologie
- 2012 •
- Fuzit •
- Link
Rok uplatnění
Fuzit - Užitný vzor
Výsledek na webu
5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity
Epigenetic 5-azacitidine (AZA) therapy of high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) represents a promising, albeit not fully understood, approach. Hematopoietic transcription factor PU.1 is dynam...
FD - Onkologie a hematologie
- 2012 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was record...
Hematology
- 2024 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Venetoclax-azacitidine is approved for treatment of patients with newly with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azac...
Hematology
- 2024 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
Academic, open label, randomized trial: G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome. GA trial is registered under EudraCT#: 2013-001639-38....
Hematology
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.
Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy - conference abstract....
Hematology
- 2023 •
- O
Rok uplatnění
O - Ostatní výsledky
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
prognosis, even after treatment with a hypomethylating agent. Azacitidine added of age or older, or both to azacitidine plus either venetoclax or placebo. All patients received a standard dose of azacitidine (75 mg per squ...
Hematology
- 2020 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs
The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs i...
FR - Farmakologie a lékárnická chemie
- 2016 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
The hypomethylating agents azacitidine (AZA) and decitabine (DEC) have been backbone therapies for older or unfit patients with newly diagnosed acute myeloid leukemia (AML) as single agents and, more recently, in combination with venetoclax....
Hematology
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Report of University Hospital Ostrava to the clinical trial protokol No: 2014-3634
Randomized, Two-Way, Crossover Study to Assess the Comparative Bioavailability of Subcutaneous Azacitidine Compared With Subcutaneous Vidaza® in Patients With Myelodysplastic Syndrome (MDS) on Azacitidine Therapy....
FD - Onkologie a hematologie
- 2016 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
- 1 - 10 out of 42 686